The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Sharon Elad*, Noam Yarom, Yehuda Zadik, Michal Kuten-Shorrer, Stephen T. Sonis

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.

Original languageEnglish
Pages (from-to)57-77
Number of pages21
JournalCa-A Cancer Journal for Clinicians
Volume72
Issue number1
DOIs
StatePublished - 1 Jan 2022

Fingerprint

Dive into the research topics of 'The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies'. Together they form a unique fingerprint.

Cite this